The Iguratimod Effect on Lupus Nephritis (IGeLU)

Inclusion Criteria: * Active lupus nephritis: * Fulfill ACR classification criteria (2009) for SLE * Proteinuria ≥1g/24h at screening * Nephritis of class III, IV, V, III+IV or IV+V, confirmed by renal pathology within 90 days prior to screening * Body weight ≥40kg * SLE-2K score ≥8 * Agreement of contraception * Informed consent obtained Exclusion Criteria: * Active severe SLE-driven renal disease or unstable renal disease at screening * Active severe or unstable neuropsychiatric SLE * Clinically significant active infection including ongoing and chronic infections * History of receiving cyclophosphamide, azathioprine, tacrolimus , mycophenolate moetil or rituximab treatment with 90 days prior to screening * History of human immunodeficiency virus (HIV) * Confirmed Positive tests for hepatitis B or positive test for hepatitis C * Active tuberculosis * Live or attenuated vaccine within 4 weeks prior to screening * Subjects with significant hematologic abnormalities * Abnormal liver function test at screening (ALT, AST or total bilirubin over 2 fold of upper normal level * History of peptic ulcer or GI bleeding; treatment with warfarin or other anticoagulants within last 14 days